Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patients

Parkinsonism and Related Disorders

Volumn 23, Issue , 2016, Pages 17-22

  Borgemeester, Robbert W K ^a   Drent, Martje ^a   van Laar, Teus ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Apomorphine; Dyskinesia; Motor fluctuations; Parkinson's disease; Visual hallucinations

Indexed keywords

APOMORPHINE; LEVODOPA; ANTIPARKINSON AGENT;

AGED; ARTICLE; CONTINUOUS INFUSION; DISEASE DURATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUTCHMAN; DYSKINESIA; FOLLOW UP; HEMOLYTIC ANEMIA; HOSPITAL DISCHARGE; HUMAN; HYPERVENTILATION; LONG TERM CARE; MAJOR CLINICAL STUDY; NAUSEA; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PARKINSON DISEASE; PERIPHERAL EDEMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUBCUTANEOUS NODULE; TACHYCARDIA; TREATMENT DURATION; VISUAL HALLUCINATION; VOMITING; COMPLICATION; FEMALE; HALLUCINATIONS; MALE; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

AGED; ANTIPARKINSON AGENTS; APOMORPHINE; FEMALE; HALLUCINATIONS; HUMANS; INFUSIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PARKINSON DISEASE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84950123709     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2015.11.013     Document Type: Article

References (26)

1. Grandas F. Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson's disease. Expert Rev. Neurother. 2013, 13:1343-1353. 10.1586/14737175.2013.839235.
2. Martinez-Martin P., Reddy P., Antonini A., Henriksen T., Katzenschlager R., Odin P., et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect. J. Parkinsons Dis. 2011, 1:197-203. 10.3233/JPD-2011-11037.
3. Martinez-Martin P., Reddy P., Katzenschlager R., Antonini A., Todorova A., Odin P., et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. Mov. Disord. 2015, 30:510-516. 10.1002/mds.26067.
4. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 1992, 55:181-184. 10.1136/jnnp.55.3.181.
5. Volkmann J., Albanese A., Antonini A., Chaudhuri K.R., Clarke C.E., de Bie R.M.A., et al. Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. J. Neurol. 2013, 260:2701-2714. 10.1007/s00415-012-6798-6.
6. García-Ruiz P.J., Sesar-Ignacio A., Ares-Pensado B., Castro-García A., Alonso-Frech F., Alvarez-López M., et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Mov. Disord. 2008, 23:1130-1136. 10.1002/mds.22063.
7. Esselink R.A.J., de Bie R.M.A., de Haan R.J., Lenders M.W.P.M., Nijssen P.C.G., Staal M.J., et al. Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: a randomized trial. Neurology 2004, 62:201-207. 10.1212/01.WNL.0000103235.12621.C3.
8. Bhasin M., Rowan E., Edwards K., McKeith I. Cholinesterase inhibitors in dementia with Lewy bodies-a comparative analysis. Int. J. Geriatr. Psychiatry 2007, 22:890-895. 10.1002/gps.1759.
9. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B 1995, 57:289-300.
10. Manson A.J., Turner K., Lees A.J. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov. Disord. 2002, 17:1235-1241. 10.1002/mds.10281.
11. Tyne H.L., Parsons J., Sinnott A., Fox S.H., Fletcher N.A., Steiger M.J. A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease. J. Neurol. 2004, 251:1370-1374. 10.1007/s00415-004-0547-4.
12. Rambour M., Moreau C., Salleron J., Devos D., Kreisler A., Mutez E., et al. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients]. Rev. Neurol. Paris. 2014, 170:205-215. 10.1016/j.neurol.2013.10.012.
13. Antonini A., Isaias I.U., Rodolfi G., Landi A., Natuzzi F., Siri C., et al. A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J. Neurol. 2011, 258:579-585. 10.1007/s00415-010-5793-z.
14. Pietz K., Hagell P., Odin P. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. J. Neurol. Neurosurg. Psychiatry 1998, 65:709-716. 10.1136/jnnp.65.5.709.
15. Acland K.M., Churchyard A., Fletcher C.L., Turner K., Lees A., Dowd P.M. Panniculitis in association with apomorphine infusion. Br. J. Dermatol 1998, 138:480-482. 10.1046/j.1365-2133.1998.02128.x.
16. van Laar T., van Hilten B., Neef C., Rutgers A.W.F., Pavel S., Bruijn A. The role of EDTA in provoking allergic reactions to subcutaneous infusion of apomorphine in patients with Parkinson's disease: a histologic study. Mov. Disord. 1998, 13:52-55. 10.1002/mds.870130113.
17. Thong B.Y.-H., Tan T.-C. Epidemiology and risk factors for drug allergy. Br. J. Clin. Pharmacol. 2011, 71:684-700. 10.1111/j.1365-2125.2010.03774.x.
18. Katzenschlager R., Hughes A., Evans A., Manson A.J., Hoffmann M., Swinn L., et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov. Disord. 2005, 20:151-157. 10.1002/mds.20276.
19. van Laar T., Postma A.G., Drent M. Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations. Park. Relat. Disord. 2010, 16:71-72. 10.1016/j.parkreldis.2009.05.006.
20. Ellis C., Lemmens G., Parkes J.D., Abbott R.J., Pye I.F., Leigh P.N., et al. Use of apomorphine in Parkinsonian patients with neuropsychiatric complications to oral treatment. Park. Relat. Disord. 1997, 3:103-107. 10.1016/S1353-8020(97)00009-6.
21. Reuter I., Ellis C.M., Ray Chaudhuri K. Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. Acta Neurol. Scand. 1999, 100:163-167.
22. Pollak P., Mallaret M., Gaio J.M., Hommel M., Perret J. Blood pressure effects of apomorphine and domperidone in parkinsonism. Adv. Neurol. 1987, 45:263-266.
23. Merello M., Pirtosek Z., Bishop S., Lees A.J. Cardiovascular reflexes in Parkinson's disease: effect of domperidone and apomorphine. Clin. Auton. Res. 1992, 2:215-219. 10.1007/BF01819541.
24. van der Marck M.A., Dicke H.C., Uc E.Y., Kentin Z.H.A., Borm G.F., Bloem B.R., et al. Body mass index in Parkinson's disease: a meta-analysis. Park. Relat. Disord. 2012, 18:263-267. 10.1016/j.parkreldis.2011.10.016.
25. Merola A., Zibetti M., Angrisano S., Rizzi L., Lanotte M., Lopiano L. Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson's disease. Mov. Disord. 2011, 26:664-670. 10.1002/mds.23524.
26. Rieu I., Derost P., Ulla M., Marques A., Debilly B., De Chazeron I., et al. Body weight gain and deep brain stimulation. J. Neurol. Sci. 2011, 310:267-270. 10.1016/j.jns.2011.06.055.